{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:32Z","timestamp":1786991072373,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113311","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T22:03:59Z","timestamp":1729721039000},"page":"113311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Bortezomib induces cell apoptosis and increases the efficacy of \u03b1PD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1"],"prefix":"10.1016","volume":"143","author":[{"given":"Fengyu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-5159","authenticated-orcid":false,"given":"Xiaoxuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2024.113311_b0005","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1016\/S2352-3026(23)00173-4","article-title":"Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures","volume":"10","author":"Smit","year":"2023","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.intimp.2024.113311_b0010","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.2147\/OTT.S142482","article-title":"Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors","volume":"10","author":"Xu","year":"2017","journal-title":"Oncotarg. Therapy"},{"issue":"3","key":"10.1016\/j.intimp.2024.113311_b0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood advances"},{"issue":"9","key":"10.1016\/j.intimp.2024.113311_b0020","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Tang","year":"2017","journal-title":"Blood: J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113311_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2024.113311_b0030","doi-asserted-by":"crossref","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2024.113311_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2020.01.008","article-title":"Coupling conjugation and deconjugation activities to achieve cellular ubiquitin dynamics","volume":"45","author":"Nielsen","year":"2020","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.intimp.2024.113311_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2020.03.008","article-title":"Dissenting degradation: Deubiquitinases in cell cycle and cancer","author":"Bonacci","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113311_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1038","article-title":"Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia","volume":"12","author":"Jiang","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113311_b0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","article-title":"Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation","volume":"20","author":"Shi","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2024.113311_b0055","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1007\/s11033-011-1309-x","article-title":"Expression of the novel human gene, UBE2Q1, in breast tumors","volume":"39","author":"Seghatoleslam","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2024.113311_b0060","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1007\/s11033-013-2824-8","article-title":"UBE2Q1 expression in human colorectal tumors and cell lines","volume":"40","author":"Shafiee","year":"2013","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2024.113311_b0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1620\/tjem.242.93","article-title":"Hypomethylated ubiquitin-conjugating enzyme2 Q1 (UBE2Q1) gene promoter in the serum is a promising biomarker for hepatitis b virus-associated hepatocellular carcinoma","volume":"242","author":"Hu","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.113311_b0070","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.7314\/APJCP.2015.16.9.3723","article-title":"UBE2Q1 in a human breast carcinoma cell line: overexpression and interaction with p53","volume":"16","author":"Shafiee","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.intimp.2024.113311_b0075","unstructured":"H.V.V. Mr, DDX3 in cancer: Identifying Motives, Targets and Partners in Crime, 2017."},{"issue":"4","key":"10.1016\/j.intimp.2024.113311_b0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/wrna.1165","article-title":"The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism","volume":"4","author":"Soto-Rifo","year":"2013","journal-title":"WIREs RNA"},{"key":"10.1016\/j.intimp.2024.113311_b0085","article-title":"DDX3 interacts with USP9X and participates indeubiquitination of theanti-apoptoticproteinMCL1","author":"Lai","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2024.113311_b0090","doi-asserted-by":"crossref","DOI":"10.2174\/09298673113206660306","article-title":"Stimulation of DDX3 expression by ginsenoside Rg3 through the Akt\/p53 pathway activates the innate immune response via TBK1\/IKK\u03b5\/IRF3 signalling","author":"Choi","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.intimp.2024.113311_b0095","article-title":"DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway","volume":"21","author":"Hh","year":"2015","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.intimp.2024.113311_b0100","first-page":"883","article-title":"A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression","volume":"39","author":"Yu","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2024.113311_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000986","article-title":"Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion","author":"Wang","year":"2010","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2024.113311_b0110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1099\/vir.0.015909-0","article-title":"Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein","volume":"91","author":"Angus","year":"2009","journal-title":"J. Gen. Virol."},{"issue":"28","key":"10.1016\/j.intimp.2024.113311_b0115","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1038\/onc.2008.33","article-title":"Oncogenic role of DDX3 in breast cancer biogenesis","volume":"27","author":"Botlagunta","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2024.113311_b0120","article-title":"The prognostic effect of DDX3 upregulation in distant breast cancer metastases","volume":"34","author":"Marise","year":"2016","journal-title":"Clin. Exp. Metast."},{"issue":"7","key":"10.1016\/j.intimp.2024.113311_b0125","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1158\/1078-0432.CCR-10-2316","article-title":"Reduced p21WAF1\/CIP1 via Alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus\u2013associated lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.intimp.2024.113311_b0130","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/onc.2013.107","article-title":"DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2\/Slug\/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer","volume":"33","author":"Wu","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2024.113311_b0135","doi-asserted-by":"crossref","first-page":"21483","DOI":"10.1038\/srep21483","article-title":"DDX3 promotes tumor invasion in colorectal cancer via the CK1\u03b5\/Dvl2 axis","volume":"6","author":"He","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.113311_b0140","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.7150\/thno.18175","article-title":"The YAP1\/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer","volume":"7","author":"De-Wei","year":"2017","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.intimp.2024.113311_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.154","article-title":"Natural HDAC-1\/8 inhibitor baicalein exerts therapeutic effect in CBF-AML","volume":"10","author":"Yu","year":"2020","journal-title":"Clinical and translational medicine"},{"issue":"8","key":"10.1016\/j.intimp.2024.113311_b0150","first-page":"131","article-title":"Apoptosis\u2014a distinctive form of cell death as biochemical, molecular and morphological changes","volume":"5","author":"Bhaskar","year":"2016","journal-title":"Int J Sci Res"},{"issue":"6","key":"10.1016\/j.intimp.2024.113311_b0155","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.200207071","article-title":"Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli","volume":"159","author":"Arnoult","year":"2002","journal-title":"J. Biophys. Biochem. Cytol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113311_b0160","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1158\/0008-5472.CAN-21-2076","article-title":"Tumor intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality","volume":"82","author":"Kornepati","year":"2022","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.113311_b0165","doi-asserted-by":"crossref","first-page":"e854","DOI":"10.1016\/S2352-3026(22)00246-0","article-title":"The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA","volume":"9","author":"Kantarjian","year":"2022","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.intimp.2024.113311_b0170","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"1","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Disc."},{"issue":"11","key":"10.1016\/j.intimp.2024.113311_b0175","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/gutjnl-2022-329134","article-title":"Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-\u03b3 signalling","volume":"72","author":"Cao","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113311_b0180","article-title":"The chemokines initiating and maintaining immune hot phenotype are prognostic in ICB of HNSCC","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2024.113311_b0185","first-page":"1","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a network meta-analysis of the current evidence","volume":"3","author":"Ouyang","year":"2024","journal-title":"Acta Mater. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.113311_b0190","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113311_b0195","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41467-024-45471-0","article-title":"Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche","volume":"15","author":"Dawson","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2024.113311_b0200","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00277-016-2915-4","article-title":"Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms","volume":"96","author":"Choi","year":"2017","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113311_b0205","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2024.113311_b0210","article-title":"PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation","author":"Hu","year":"2024","journal-title":"Cancer Lett."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924018332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924018332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:30:51Z","timestamp":1736285451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924018332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"alternative-id":["S1567576924018332"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113311","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib induces cell apoptosis and increases the efficacy of \u03b1PD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113311"}}